34211-04-6

Usage

Family

Benzothiazole

Structure

Contains a phenyl group attached to a methanamine moiety

Usage

Building block in organic synthesis

Application

Production of pharmaceuticals and agrochemicals

Biological activities

Antiviral, antibacterial, antifungal, and anticancer properties

Potency

Potent inhibitor of protein kinase C

Importance

Valuable tool for studying the functions of protein kinase C in cellular processes

Upstream product

• 56-91-7 p-aminomethylbenzoic acid 
• 137-07-5 2-amino-benzenethiol 
• 99-94-5 p-Toluic acid 
• 16112-21-3 2-(4-methylphenyl)-1,3-benzothiazole 
• 36078-45-2 N-(4-benzothiazol-2-yl-benzyl)-phthalimide 

Downstream Products

• 1429744-84-2 N-(4-(benzo[d]thiazol-2-yl)benzyl)-2-(4-(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)phenyl)acetamide 
• 1429744-80-8 N-(4-(benzo[d]thiazol-2-yl)benzyl)-2-(4-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)phenyl)acetamide 
• 1429744-81-9 1-(4-(2-(benzo[d]thiazol-2-yl)pyrrolidin-1-yl)-4-oxobutyl)-3-(benzyloxy)-2-methylpyridin-4(1H)-one 
• 36078-41-8 N-(4-benzothiazol-2-yl-benzyl)-2,2-dichloro-acetamide 

Relevant academic research and scientific papers

Influence of the methylene group between azadithiolate nitrogen atom and phenyl moiety on the protophilic properties of [FeFe]-hydrogenase model complexes

An [FeFe]-hydrogenase mimic 4 with functional benzyl moiety covalently linked to the azadithiolate ligand was synthesized. The structure, protonation, and electrochemical properties of 4 and a phenyl substituted analogue (coded as 3) were simultaneously s

Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease

Alzheimer's disease (AD) is a multifactorial disorder with several target proteins contributing to its etiology. In search for multifunctional anti-AD drug candidates, taking into account that the acetylcholinesterase (AChE) and beta-amyloid (Aβ) aggregat

Multifunctional iron-chelators with protective roles against neurodegenerative diseases

The multifactorial nature of Alzheimer's disease (AD), and the absence of a disease modifying drug, makes the development of new multifunctional drugs an attractive therapeutic strategy. Taking into account the hallmarks of AD patient brains, such as low levels of acetylcholine, misfolding of proteins and associated beta-amyloid (Aβ) aggregation, oxidative stress and metal dyshomeostasis, we have developed a series of compounds that merge three different approaches: metal attenuation, anti-Aβ aggregation and anti-acetylcholinesterase activity. Therefore, 3-hydroxy-4-pyridinone (3,4-HP) and benzothiazole molecular moieties were selected as starting frameworks due to their well known affinity for iron and Aβ peptides, respectively. The linkers between these two main functional groups were selected on the basis of virtual screening, so that the final molecule could further inhibit the acetylcholinesterase, responsible for the cholinergic losses. We describe herein the design and synthesis of the new hybrid compounds, followed by the assessment of solution properties, namely iron chelation and anti-oxidant capacity. The compounds were bioassayed for their capacity to inhibit AChE, as well as self- and Zn mediated-Aβ1-42 aggregation. Finally, we assessed their effects on the viability of neuronal cells stressed with Aβ42.